-
Publication Venue For
-
Provider response and follow-up to parental declination of HPV vaccination..
40:344-350.
2022
-
Towards a population-based threshold of protection for COVID-19 vaccines..
40:306-315.
2022
-
Children are the key to the Endgame: A case for routine pediatric COVID vaccination..
39:5333-5336.
2021
-
Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models..
39:5358-5367.
2021
-
Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases..
39:5233-5239.
2021
-
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period..
39:4641-4650.
2021
-
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial..
39:3879-3891.
2021
-
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older..
39:1339-1348.
2021
-
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial..
38:6930-6940.
2020
-
Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh: A case-control study..
38:6508-6516.
2020
-
Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants..
38:5355-5363.
2020
-
Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status..
38:4869-4876.
2020
-
Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women..
38:4520-4523.
2020
-
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination..
38:1678-1689.
2020
-
Immunological mechanisms of inducing HIV immunity in infants..
38:411-415.
2020
-
Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology..
38:187-193.
2020
-
Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis..
37:5535-5543.
2019
-
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents..
37:5161-5170.
2019
-
An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults..
37:4222-4230.
2019
-
Malaria vaccine trials in pregnant women: An imperative without precedent..
37:763-770.
2019
-
Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women..
36:8054-8061.
2018
-
Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles..
36:6345-6353.
2018
-
Protein deficiency reduces efficacy of oral attenuated human rotavirus vaccine in a human infant fecal microbiota transplanted gnotobiotic pig model..
36:6270-6281.
2018
-
Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women..
36:6354-6360.
2018
-
Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines..
36:5600-5608.
2018
-
Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine..
36:5325-5332.
2018
-
Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants..
36:5020-5029.
2018
-
Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women..
36:4663-4671.
2018
-
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors..
36:3247-3253.
2018
-
Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study..
36:2356-2363.
2018
-
The Advisory Committee on Immunization Practices recommendation regarding the use of live influenza vaccine: A rejoinder..
36:343-344.
2018
-
The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children..
35:6664-6671.
2017
-
The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged..
35:3700-3708.
2017
-
Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015..
35:2279-2287.
2017
-
Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials..
35:1184-1193.
2017
-
DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies..
35:929-937.
2017
-
Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques..
35:639-646.
2017
-
Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data..
34:6084-6092.
2016
-
Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV..
34:5886-5894.
2016
-
Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations..
34:5344-5351.
2016
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine..
34:547-554.
2016
-
Use of mobile phones for improving vaccination coverage among children living in rural hard-to-reach areas and urban streets of Bangladesh..
34:276-283.
2016
-
A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice..
33:6596-6603.
2015
-
Initiation & completion rates of hepatitis A vaccination among US pediatric populations born between 2005 and 2009..
33:6871-6877.
2015
-
Maternal benefits of immunization during pregnancy..
33:6436-6440.
2015
-
Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials..
33:6241-6249.
2015
-
Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity..
33:5715-5722.
2015
-
Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine..
33:5425-5431.
2015
-
Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers..
33:4141-4145.
2015
-
Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination..
33:3609-3613.
2015
-
Influenza vaccination in children with neurologic or neurodevelopmental disorders..
33:2322-2327.
2015
-
Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials..
33:2347-2353.
2015
-
Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals..
33:1953-1958.
2015
-
Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua..
33:222-227.
2015
-
Maternal determinants of timely vaccination coverage among infants in rural Bangladesh..
32:5514-5519.
2014
-
Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection..
32:3995-4000.
2014
-
The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid..
32:3752-3758.
2014
-
IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection..
32:3595-3603.
2014
-
Perceptions of personal belief vaccine exemption policy: a survey of Arizona vaccine providers..
32:3630-3635.
2014
-
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children..
31:5706-5712.
2013
-
Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?.
31:5500-5505.
2013
-
Research on vaccines during pregnancy: protocol design and assessment of safety..
31:4274-4279.
2013
-
Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments..
31:4264-4273.
2013
-
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario..
31:3025-3033.
2013
-
Evaluation of vaccine-induced antibody responses: impact of new technologies..
31:2756-2761.
2013
-
A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen..
31:1480-1489.
2013
-
Disparate adjuvant properties among three formulations of "alum"..
31:653-660.
2013
-
Association of vaccine-related attitudes and beliefs between parents and health care providers.
31:4591-4595.
2013
-
Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform..
30:7265-7270.
2012
-
Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009..
30:4240-4248.
2012
-
Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody..
30:4233-4239.
2012
-
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein..
30:2749-2759.
2012
-
Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study..
30:2047-2050.
2012
-
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge..
30:1830-1840.
2012
-
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses..
30:1737-1745.
2012
-
Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques..
30:78-94.
2011
-
Increasing vaccine potency through exosome antigen targeting..
29:9361-9367.
2011
-
Healthy-days time equivalents for outcomes of acute rotavirus infections..
29:8086-8093.
2011
-
Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults..
29:5666-5674.
2011
-
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges..
29:5611-5622.
2011
-
Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant..
29:4058-4066.
2011
-
Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs..
29:4067-4076.
2011
-
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals..
29:3021-3030.
2011
-
The HPV vaccine: are dosing recommendations being followed?.
29:2548-2554.
2011
-
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects..
29:1948-1958.
2011
-
Employee designation and health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital..
29:1762-1769.
2011
-
Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries..
29:878-885.
2011
-
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age..
28:7865-7872.
2010
-
Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1..
28:6901-6914.
2010
-
Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques..
28:6483-6490.
2010
-
Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally?.
28:4376-4383.
2010
-
Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination..
28:3672-3678.
2010
-
Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus..
28:1702-1708.
2010
-
Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge..
28:299-308.
2009
-
Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals..
27:7141-7148.
2009
-
Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors..
27:5837-5845.
2009
-
Development and use of SIV-based Integrase defective lentiviral vector for immunization..
27:4622-4629.
2009
-
Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates..
27:4709-4717.
2009
-
Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV..
27:3754-3765.
2009
-
Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort.
2018